» Articles » PMID: 26221893

A Case of Abdominal Pain with Dyslipidemia: Difficulties Diagnosing Cholesterol Ester Storage Disease

Overview
Date 2015 Jul 30
PMID 26221893
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Cholesterol ester storage disease is an exceptionally rare dyslipidemia with less than 150 cases reported in the medical literature. The diagnosis of Cholesterol Ester Storage Disease is often missed by virtue of the fact that the symptoms mimic both inborn metabolic defects and hepatic steatosis. Patients with Cholesterol Ester Storage Disease usually present with atypical complaints including abdominal pain from altered gut motility. Blood analysis typically reveals abnormal liver function tests with coincident dyslipidemia. We present a case of a young woman with Cholesterol Ester Storage Disease who was followed over two decades. We discuss issues common to her initial protracted diagnosis with management options over time.

Citing Articles

Recent insights into lysosomal acid lipase deficiency.

Korbelius M, Kuentzel K, Bradic I, Vujic N, Kratky D Trends Mol Med. 2023; 29(6):425-438.

PMID: 37028992 PMC: 7614602. DOI: 10.1016/j.molmed.2023.03.001.


Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency.

Di Rocco M, Pisciotta L, Madeo A, Bertamino M, Bertolini S Orphanet J Rare Dis. 2018; 13(1):24.

PMID: 29374495 PMC: 5787265. DOI: 10.1186/s13023-018-0768-8.

References
1.
Aslanidis C, Ries S, Fehringer P, Buchler C, Klima H, Schmitz G . Genetic and biochemical evidence that CESD and Wolman disease are distinguished by residual lysosomal acid lipase activity. Genomics. 1996; 33(1):85-93. DOI: 10.1006/geno.1996.0162. View

2.
Decarlis S, Agostoni C, Ferrante F, Scarlino S, Riva E, Giovannini M . Combined hyperlipidaemia as a presenting sign of cholesteryl ester storage disease. J Inherit Metab Dis. 2009; 32 Suppl 1:S11-3. DOI: 10.1007/s10545-008-1027-2. View

3.
P Phan B, Dayspring T, Toth P . Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012; 8:415-27. PMC: 3402055. DOI: 10.2147/VHRM.S33664. View

4.
Pagani F, Pariyarath R, Garcia R, Stuani C, Burlina A, Ruotolo G . New lysosomal acid lipase gene mutants explain the phenotype of Wolman disease and cholesteryl ester storage disease. J Lipid Res. 1998; 39(7):1382-8. View

5.
Saito S, Ohno K, Suzuki T, Sakuraba H . Structural bases of Wolman disease and cholesteryl ester storage disease. Mol Genet Metab. 2011; 105(2):244-8. DOI: 10.1016/j.ymgme.2011.11.004. View